Eloxx Pharma Announces Orphan Drug Designation In The U.S. And Europe For ELX-02 In Mucopolysacchardisis Type 1 (MPS 1)

Published: Nov 08, 2016

NESS ZIONA, Israel and WALTHAM, Massachusetts, November 7, 2016 /PRNewswire/ --

Eloxx Pharmaceuticals, a biotechnology company focused on discovery, development and commercialization of compounds for the treatment of genetic diseases caused by nonsense mutations, announced today that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) has granted orphan drug designation to its lead propriety drug candidate, ELX-02 for the treatment of mucopolysaccharidosis type 1 (MPS I).

Back to news